Tamás G Gergely, Zsófia D Drobni, Marinos Kallikourdis, Han Zhu, Wouter C Meijers, Tomas G Neilan, Tienush Rassaf, Péter Ferdinandy, Zoltán V Varga
Immune checkpoint molecules are physiological regulators of the adaptive immune response. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting programmed cell death protein 1 or cytotoxic T lymphocyte-associated protein 4, have revolutionized cancer treatment and their clinical use is increasing. However, ICIs can cause various immune-related adverse events, including acute and chronic cardiotoxicity. Of these cardiovascular complications, ICI-induced acute fulminant myocarditis is the most studied, although emerging clinical and preclinical data are uncovering the importance of other ICI-related chronic cardiovascular complications, such as accelerated atherosclerosis and non-myocarditis-related heart failure...
January 26, 2024: Nature Reviews. Cardiology